Skyrizi 150 MG/ML penml
Ended Awarded Last action
- Contract number
- SPE2DR26F5QT5
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $36,734
Award facts
- Contract value 100% obligated
- $36,734.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $36,734.41 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/mL on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price contract, issued without a set-aside designation, was competitively awarded and performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI (risankizumab) is a biologic immunosuppressant medication used in the treatment of inflammatory skin conditions including plaque psoriasis and psoriatic arthritis, representing a specialized pharmaceutical commodity within the military healthcare supply chain.
This delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at up to $999,999,999.00 through December 31, 2031. The IDC enables DLA to procure a full range of brand-name and generic medications, specialty drugs, vaccines, and medical supplies to support military healthcare programs globally. AmerisourceBergen's consistent receipt of federal pharmaceutical contracts underscores its established capability to meet government requirements for critical medical commodities across multiple therapeutic domains serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F5QT5?
SPE2DR26F5QT5 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F5QT5 worth?
The government has obligated $36,734 on SPE2DR26F5QT5.
Is contract SPE2DR26F5QT5 an order under another contract?
Yes. SPE2DR26F5QT5 is a delivery order under SPE2DR25D3003, an indefinite delivery contract.
Was contract SPE2DR26F5QT5 competed?
The extent of competition for SPE2DR26F5QT5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award